recipients of 400 mg of the supplement who were 55 years of age or younger had significantly higher geometric mean antibody titres against influenza a/new caledonia 21 days after vaccination (p = 0.047) and against b/yamanashi 7 days after vaccination (p = 0.034); the trends were nonsignificant for titres against a/panama.